title: Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success.
abstract: The reliability of response to treatment is an important component of erectile dysfunction (ED) treatment. This study examined the reliability of tadalafil once daily (that is, successful attempts/total attempts) following initial successful intercourse. Data pooled from two randomized, double-blind, placebo-controlled trials of men with ED who received tadalafil 2.5 mg (N=96), tadalafil 5 mg (N=206) or placebo (N=148) once daily were analyzed to determine the first-attempt success rate and subsequent reliability of response. The first-attempt success rate (Sexual Encounter Profile question 3 (SEP3)) was significantly higher among men taking tadalafil 2.5 mg (45.7%) and 5 mg (55.2%) compared to placebo (28.5%; P<0.05 and P<0.001, respectively). Furthermore, following initial success, men taking tadalafil 5 mg had a significantly greater proportion of successful intercourse (SEP3) on subsequent attempts (85.9%, P<0.001) compared to men taking placebo (70.2%). Overall, men with ED taking tadalafil once daily experienced a high rate of reliability of efficacy.
authors: Maimonides Medical Center and Columbia University, New York, NY, USA. rshabsigh@maimonidesmed.org
authors: R
authors: R
authors: Shabsigh
authors: C
authors: C
authors: Donatucci
authors: R
authors: R
authors: Costabile
authors: M A
authors: MA
authors: Perelman
authors: P
authors: P
authors: Burns
authors: H
authors: H
authors: Zeigler
authors: D G
authors: DG
authors: Wong
mesh_terms: D000368:Aged; D002243:Carbolines / Q000008:administration & dosage / Q000627:therapeutic use*; D003075:Coitus; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5 / Q000008:administration & dosage; D004311:Double-Blind Method; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D015203:Reproducibility of Results; D019529:Sexuality; D000068581:Tadalafil; D016896:Treatment Outcome
chemical_list: D002243:Carbolines; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors; D000068581:Tadalafil; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5